113-92-8CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1SOYKEARSMXGVTM-UHFFFAOYSA-NChlorphenamine is a tertiary amino compound that is propylamine which is substituted at position 3 by a pyridin-2-yl group and a p-chlorophenyl group and in which the hydrogens attached to the nitrogen are replaced by methyl groups. A histamine H1 antagonist, it is used to relieve the symptoms of hay fever, rhinitis, urticaria, and asthma. It has a role as an antidepressant, a H1-receptor antagonist, a histamine antagonist, an anti-allergic agent, a serotonin uptake inhibitor and an antipruritic drug. It is a member of pyridines, a tertiary amino compound and a member of monochlorobenzenes.
113-92-8、132-22-9UV max absorption (water): 261 nm (E=5760), Solubility in mg/ml at 25 °C: Ethanol 330; chloroform 240; water 160; methanol 130; pH of a 2% aqueous solution about 5 /Maleate/
160.0 mg/mL at 25 °C
Breast Feeding; Lactation; Milk, Human; Antihistamines; Antipruritics
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。
Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).
SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.
Concurrent use /of ototoxic medications/ with antihistamines may mask the symptoms of ototoxicity such as tinnitus, dizziness, or vertigo. /Antihistamines/
Concurrent use of monoamine oxidase (MAO) inhibitors with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines; concurrent use is not recommended. /Antihistamines/
Concurrent use /with alcohol or other CNS depression-producing medications/ may potentiate the CNS depressant effects of either these medications or antihistamines; also, concurrent use of maprotiline or tricyclic antidepressants may potentiate the anticholinergic effects of either antihistamines or these medications. /Antihistamines/
R06AB54
R - Respiratory system
QR - Respiratory system
In allergic reactions an allergen interacts with and cross-links surface IgE antibodies on mast cells and basophils. Once the mast cell-antibody-antigen complex is formed, a complex series of events occurs that eventually leads to cell-degranulation and the release of histamine (and other chemical mediators) from the mast cell or basophil. Once released, histamine can react with local or widespread tissues through histamine receptors. Histamine, acting on H<sub>1</sub>-receptors, produces pruritis, vasodilatation, hypotension, flushing, headache, tachycardia, and bronchoconstriction. Histamine also increases vascular permeability and potentiates pain. Chlorpheniramine, is a histamine H1 antagonist (or more correctly, an inverse histamine agonist) of the alkylamine class. It competes with histamine for the normal H<sub>1</sub>-receptor sites on effector cells of the gastrointestinal tract, blood vessels and respiratory tract. It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory allergies.
Chlorpheniramine binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine.
Antihistamines used in the treatment of allergy act by competing with histamine for H1-receptor sites on effector cells. They thereby prevent, but do not reverse, responses mediated by histamine alone. Antihistamines antagonize, in varying degrees, most of the pharmacological effects of histamine, including urticaria and pruritus. Also, the anticholinergic actions of most antihistamines provide a drying effect on the nasal mucosa. /Antihistamines/
H1 antagonists inhibit most responses of smooth muscle to histamine. Antagonism of the constrictor action of histamine on respiratory smooth muscle is easily shown in vivo and in vitro. /Histamine Antagonists: H1 Antagonists/
H1 antagonists strongly block the action of histamine that results in increased permeability and formation of edema and wheal. /Histamine Antagonists: H1 Antagonists/
読み込み中…
DTXSID0022804CHEMBL505CHEBI:52010Anticholinergic effects may be potentiated when /anticholinergics or other medications with anticholinergic activity/ are used concurrently with antihistamines; patients should be advised to report occurrence of gastrointestinal problems promptly since paralytic ileus may occur with concurrent therapy. /Antihistamines/
Concurrent use /of other photosensitizing medications/ with antihistamines may cause additive photosensitizing effects. /Antihistamines/
The following link will take the user to the National Toxicology Program (NTP) Test Agent Search Results page, which tabulates all of the "Standard Toxicology & Carcinogenesis Studies", "Developmental Studies", and "Genetic Toxicity Studies" performed with this chemical. Clicking on the "Testing Status" link will take the user to the status (i.e., in review, in progress, in preparation, on test, completed, etc.) and results of all the studies that the NTP has done on this chemical. /Chlorpheniramine maleate/ [http://ntp-apps.niehs.nih.gov/ntp_tox/index.cfm?fuseaction=ntpsearch.searchresults&searchterm=113-92-8]
SYMPTOMATOLOGY: 1. CENTRAL NERVOUS DEPRESSION IS USUALLY DOMINANT REACTION IN ADULTS; IT IS EVIDENCED BY DROWSINESS, LETHARGY, FATIGUE, HYPNOSIS, & COMA. RELATED NERVOUS SYMPTOMS INCL VERTIGO, ATAXIA, TINNITUS, & BLURRED VISION. /ANTIHISTAMINICS/
SYMPTOMATOLOGY: 2. CENTRAL NERVOUS HYPEREXCITABILITY OFTEN FOLLOWS INITIAL SEDATION; IN CHILDREN EXCITEMENT IS OFTEN FIRST EVIDENCE OF POISONING. STIMULANT PHASE BRINGS TREMORS, ANXIETY, INSOMNIA, EXCITEMENT, HALLUCINATIONS, DELIRIUM, TOXIC PSYCHOSIS & CONVULSIONS... /ANTIHISTAMINICS/
SYMPTOMATOLOGY: 3. DANGEROUS HYPERPYREXIA MAY OCCUR IN POISONED CHILDREN... 4. GASTROINTESTINAL REACTIONS INCL DRY MOUTH, ANOREXIA, NAUSEA, VOMITING, ABDOMINAL DISTRESS, CONSTIPATION, &/OR DIARRHEA. /ANTIHISTAMINICS/
SYMPTOMATOLOGY: 5. TERMINAL PHASE IS ONE OF SEVERE CENTRAL NERVOUS DEPRESSION, WITH DEATH FROM RESP ARREST OR CARDIOVASCULAR COLLAPSE. /ANTIHISTAMINICS/
For more Human Toxicity Excerpts (Complete) data for CHLORPHENIRAMINE (10 total), please visit the HSDB record page.
Drug-Induced Liver Injury Severity and Toxicity (DILIst)
chlorpheniramine
DILI Negative
Oral
DOI:10.1016/j.drudis.2019.09.022
LARGE DOSES PRODUCE CONVULSIONS IN EXPTL ANIMALS. /ANTIHISTAMINES/
SMALL DOSES OF SOME ANTIHISTAMINICS PRODUCE DEPRESSION, DROWSINESS, SALIVATION & VOMITING. /ANTIHISTAMINICS/
CHLORPHENIRAMINE MALEATE DECR ACETYLCHOLINE LEVEL IN BOTH HEMISPHERES & REST OF BRAIN. RESULTS FOR STYRAMINE ARE ALSO GIVEN.
... H1 antagonists are eliminated more rapidly by children than by adults and more slowly in those with severe liver disease. /Histamine Antagonists: H1 Antagonists/
CHLORPHENIRAMINE MALEATE, AN ANTAGONIST OF HISTAMINE, INHIBITED DEVELOPMENT OF EHRLICH ASCITES CARCINOMA WHEN GIVEN TO MICE ORALLY FOR 10 DAYS, STARTING ON DAY OF TUMOR IMPLANT.
Use is not recommended in newborn or premature infants because this age group has an increased susceptibility to anticholinergic side effects, such as central nervous system excitation, and an increased tendency toward convulsions. A paradoxical reaction characterized by hyperexcitability may occur in children taking antihistamines. /Antihistamines/
Dizziness, sedation, confusion, and hypotension may be more likely to occur in geriatric patients taking antihistamines. Geriatric patients are especially susceptible to the anticholinergic side effects, such as dryness of mouth and urinary retention (especially in males), of the antihistamines. If these side effects occur and continue or are severe, medication should probably be discontinued. /Antihistamines/
There is no specific therapy for antihistamine poisoning, and treatment is along general symptomatic and supportive lines. ... Should breathing fail, mech support of ventilation offer safer and ... effective means of maintaining resp than use of analeptics which are prone to initiative or intensify convulsive phase. /Antihistamine/
Toxicology and carcinogenesis studies of chlorpheniramine maleate (99% pure) ... were conducted by administering this chemical in deionized water by gavage to 50 male and 50 female F344/N rats and B6C3F1 mice, 5 days/wk for 103 wk. The doses used were: male rats: 0, 15, or 30 mg/kg; female rats: 0, 30, or 60 mg/kg; male mice: 0, 25, or 50 mg/kg; female mice: 0, 100, or 200 mg/kg. ... Under the conditions of these two yr studies, there was no evidence of carcinogenicity for F344/N rats or B6C3F1 mice administered chlorpheniramine maleate in deionized water, 5 days/wk for two yr. Due to high mortality in high dose female rats and high dose male mice, the sensitivity of these groups to detect carcinogenic response was reduced. /The cmpd/ had a proliferative effect on the thyroid gland of female mice, as shown by the increased evidences of follicular cell cysts and hyperplasia in both low dose and high dose groups. /Chlorpheniramine maleate/
Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).
Within the vascular tree, the H1 antagonists inhibit both the vasoconstrictor effects of histamine and, to a degree, the more rapid vasodilator effects that are mediated by H1 receptors on endothelial cells. Residual vasodilatation reflects the involvement of H2 receptors on smooth muscle and can be suppressed only by the concurrent administration of an H2 antagonist. Effects of the histamine antagonists on histamine induced changes in systemic blood pressure parallel these vascular effects. /Histamine Antagonists: H1 Antagonists/
Many of the H1 antagonists tend to inhibit responses to acetylcholine that are mediated by muscarinic receptors. These atropine like actions are sufficiently prominent in some of the drugs to be manifest during clinical usage ... . /Histamine Antagonists: H1 Antagonists/
21-27 hours
IN MAN...PLASMA T/2 OF CHLORPHENIRAMINE IS...12-15 HR...ALTHOUGH PLASMA LEVELS OF TOTAL RADIOACTIVITY ARE PROLONGED...
Elimination: 14 to 25 hours
Primarily hepatic via Cytochrome P450 (CYP450) enzymes.
MAIN SITE OF METABOLIC TRANSFORMATION IS LIVER. /ANTIHISTAMINES/
Primarily hepatic via Cytochrome P450 (CYP450) enzymes. Half Life: 21-27 hours
3U6IO1965U
CHLORPHENIRAMINE
Mechanisms of Action [MoA] - Histamine H1 Receptor Antagonists
Established Pharmacologic Class [EPC] - Histamine-1 Receptor Antagonist
Chlorpheniramine is a Histamine-1 Receptor Antagonist. The mechanism of action of chlorpheniramine is as a Histamine H1 Receptor Antagonist.
Agents, usually topical, that relieve itching (pruritus).
Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood.
Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475)
Well absorbed in the gastrointestinal tract.
STUDIES IN MAN & EXPTL ANIMALS INDICATE THAT (3)H-CHLORPHENIRAMINE MALEATE IS RAPIDLY & QUANT ABSORBED FROM GUT. ALTHOUGH PLASMA LEVELS OF TOTAL RADIOACTIVITY ARE PROLONGED, PLASMA T/2 OF CHLORPHENIRAMINE IS ONLY 12-15 HR IN MAN & 3 HR IN DOG. T/2 IN MAN IS ABOUT 3 TIMES LONGER THAN THERAPEUTIC EFFECT...
The H1 antagonists are well absorbed from the GI tract. Following oral administration, peak plasma concn are achieved in 2 to 3 hr and effects usually last 4 to 6 hr; however, some of the drugs are much longer acting ... . /Histamine Antagonists: H1 Antagonists/
H1 blockers are among the many drugs that induce hepatic microsomal enzymes, and they may facilitate their own metabolism. /Histamine Antagonists: H1 Antagonists/
MEDICATION
MEDICATION (VET):
Use (kg; approx.) in Germany (2009): >250
Used used in the prevention of the symptoms of allergic conditions such as rhinitis, urticaria, allergy, common cold, asthma and hay fever.
(1977) 5.0X10+6 G-INCL MALEATE (PRINCPL DISTS)
(1979) 2.0X10+7 G-INCL MALEATE (PRINCPL DISTS)
(1977) 1.68X10+7 GRAMS (MALEATE)
(1978) 2.13X10+7 GRAMS (MALEATE)
CONDENSATION OF 2-(P-CHLORO-ALPHA-(2-CHLOROETHYL)BENZYL)PYRIDINE WITH DIMETHYLAMINE IN THE PRESENCE OF SODAMIDE
Synthesis.
TABLETS, 4 MG; REPEAT-ACTION TABLETS, 8 & 12 MG, INJECTION; SYRUP /FROM TABLE/
GRADE: USP /MALEATE/
2-Pyridinepropanamine, .gamma.-(4-chlorophenyl)-N,N-dimethyl-: INACTIVE
TREATMENT OF BASE WITH EQUIMOLAR PORTION OF MALEIC ACID RESULTS IN FORMATION OF MALEATE. /MALEATE/
解説3-(4-chlorophenyl)-N,N-dimethyl-3-(2-pyridyl)propylamine.C16H19ClN2(274.79).クロルフェニラミンは,4-クロロベンジルシアニドと2-クロロピリジンとを縮合させ,これに2-(ジメチルアミノ)エチルクロリドを反応させ,80% H2SO4と加熱すると得られる.油状の液体.沸点142 ℃(0.13 kPa).マレイン酸塩:C16H19ClN2·C4H4O4(390.87)が実用化されている.白色の微細な結晶.融点130~135 ℃.λmax 261 nm.水,エタノール,クロロホルムに可溶.2% 水溶液の pH は約5.強力な抗ヒスタミン薬である.じんましん,枯草熱,皮膚疾患に伴う掻痒(そうよう),アレルギー性鼻炎,血管運動性鼻炎などに投与する.LD50 162 mg/kg(マウス,経口).[CAS 132-22-9][CAS 113-92-8:マレイン酸塩] 森北出版「化学辞典(第2版)
使用Chlorpheniramine is a drug in the class of first-generation antihistamines, used to help alleviate symptoms of allergic reactions potentiated by histamine release. Though it is included in many multisymptom over-the-counter cold relief medications, the Food and Drug Administration (FDA) issued a safety alert in March 2011 detailing some risks associated with these medications. The safety alert also indicated that increased enforcement of FDA laws governing the marketing of these drugs would occur, as many of the products had not been approved in their current formulations for safety, effectiveness, and quality. Chlorpheniramine is commonly used in small-animal veterinary medicine for its antihistaminic/antipruritic effects, especially for the treatment of pruritus in cats, and occasionally as a mild sedative.